Sugammadex Injection [Bridion]

University Health Network, Toronto · FDA-approved active Small molecule

Sugammadex Injection [Bridion] is a Selective relaxant binding agent Small molecule drug developed by University Health Network, Toronto. It is currently FDA-approved for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients. Also known as: Sugammadex.

Sugammadex is a selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium neuromuscular blocking agents, rapidly reversing neuromuscular blockade.

Sugammadex is a selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium neuromuscular blocking agents, rapidly reversing neuromuscular blockade. Used for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients.

At a glance

Generic name	Sugammadex Injection [Bridion]
Also known as	Sugammadex
Sponsor	University Health Network, Toronto
Drug class	Selective relaxant binding agent
Target	Rocuronium and vecuronium (steroidal neuromuscular blocking agents)
Modality	Small molecule
Therapeutic area	Anesthesia
Phase	FDA-approved

Mechanism of action

Sugammadex works by forming a tight 1:1 complex with steroidal neuromuscular blocking agents (rocuronium and vecuronium), removing them from the neuromuscular junction and plasma. This mechanism allows rapid reversal of neuromuscular blockade without the need for acetylcholinesterase inhibitors, providing faster and more reliable recovery of neuromuscular function compared to traditional reversal agents.

Approved indications

• Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery
• Reversal of deep neuromuscular blockade in anesthetized patients

Common side effects

• Nausea
• Vomiting
• Headache
• Hypotension
• Tachycardia
• Cough

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Sugammadex Injection [Bridion] CI brief — competitive landscape report
• Sugammadex Injection [Bridion] updates RSS · CI watch RSS
• University Health Network, Toronto portfolio CI

Frequently asked questions about Sugammadex Injection [Bridion]

What is Sugammadex Injection [Bridion]?

Sugammadex Injection [Bridion] is a Selective relaxant binding agent drug developed by University Health Network, Toronto, indicated for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients.

How does Sugammadex Injection [Bridion] work?

Sugammadex is a selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium neuromuscular blocking agents, rapidly reversing neuromuscular blockade.

What is Sugammadex Injection [Bridion] used for?

Sugammadex Injection [Bridion] is indicated for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients.

Who makes Sugammadex Injection [Bridion]?

Sugammadex Injection [Bridion] is developed and marketed by University Health Network, Toronto (see full University Health Network, Toronto pipeline at /company/university-health-network-toronto).

Is Sugammadex Injection [Bridion] also known as anything else?

Sugammadex Injection [Bridion] is also known as Sugammadex.

What drug class is Sugammadex Injection [Bridion] in?

Sugammadex Injection [Bridion] belongs to the Selective relaxant binding agent class. See all Selective relaxant binding agent drugs at /class/selective-relaxant-binding-agent.

What development phase is Sugammadex Injection [Bridion] in?

Sugammadex Injection [Bridion] is FDA-approved (marketed).

What are the side effects of Sugammadex Injection [Bridion]?

Common side effects of Sugammadex Injection [Bridion] include Nausea, Vomiting, Headache, Hypotension, Tachycardia, Cough.

What does Sugammadex Injection [Bridion] target?

Sugammadex Injection [Bridion] targets Rocuronium and vecuronium (steroidal neuromuscular blocking agents) and is a Selective relaxant binding agent.

Related

• Drug class: All Selective relaxant binding agent drugs
• Target: All drugs targeting Rocuronium and vecuronium (steroidal neuromuscular blocking agents)
• Manufacturer: University Health Network, Toronto — full pipeline
• Therapeutic area: All drugs in Anesthesia
• Indication: Drugs for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery
• Indication: Drugs for Reversal of deep neuromuscular blockade in anesthetized patients
• Also known as: Sugammadex